The purpose of the study was to evalute the impact of centrations were significantly higher compared to patients with mean arterial BP reduction Ͻ25% the renin-angiotensin-aldosterone (RAA) system on blood pressure (BP) response in patients with hyperten-(12.3 ± 6.7 vs 5.6 ± 4.0 pg/ml,P = 0.013). These data indicate that PRA and ANG II are the major sive emergencies and urgencies treated with intravenous enalaprilat. Thirty-five patients with a systolic determinants for BP response to enalaprilat. This relation between BP response and RAA system activity BP ( repetitive application on an ACE inhibitor in primary responders is clinically unhelpful and may result in an r = −0.49; P = 0.003; DBP: r = 0.48; P = 0.007). Nonresponders to enalaprilat exhibited significant lower unnecessary delay of an effective BP reduction. In contrast, high ANG II concentrations are associated with a pretreatment levels of PRA, angiotensin-converting enzyme (ACE) and ANG II compared to responders considerable risk for severe hypotension after enolanalaprilat application. Therefore, the status of the RAA (PRA: 5.5 ± 3.7 vs 1.1 ± 2.2 ng/ml/h, P Ͻ 0.001; ACE: 12.8 ± 3.5 vs 8.2 ± 4.8 U/l, P = 0.003; ANG II:8.7 ± 6.2 vs system determines the efficacy as well as the safety of ACE inhibitor treatment in patients with severe hyper-5.0 ± 3.8 pg/ml, P = 0.04). In patients with severe hypotension following application of enalaprilat ANG II contension.
Introduction
Hodsman et al 8 reported about a positive correlation Angiotensin-converting enzyme (ACE) inhibitors are between pretreatment ANG II levels and decrease of well established in the treatment of chronic hyperblood pressure (BP) in patients with essential hypertension, congestive heart failure and diabetic tension and severe hypertensive dysregulation. nephropathy. [1] [2] [3] [4] Recently, parenteral enalaprilat has More recently obtained data, however, are rather been recommended for the treatment of patients controversial concerning the relation between the with hypertensive crises. 5 However, some earlier renin-angiotensin-aldosterone (RAA) system and the published reports have demonstrated that the oral extent of BP reduction after ACE-inhibitor appliapplication of an ACE inhibitor was associated with cation. 13, 14 Whereas Dipette et al 13 demonstrated a a considerable risk for severe hypotension early after considerable relation between renin activity and BP drug application. 6, 7 High pretreatment levels of reduction, Strauss et al 14 failed to observe any plasma renin and angiotensin II (ANG II), prior relation between pretreatment plasma renin activity diuretic treatment and higher age were identified as (PRA) and response to treatment. risk factors for this first dose hypotension induced We, therefore, conducted a study to: (1) evaluate by an ACE inhibitor. 8, 9 These data were obtained the relation between pretreatment activity of the mainly in patients with congestive heart failure or RAA system and BP response to enalaprilat in with stenosis of the renal arteries. [10] [11] [12] Data about patients with hypertensive crises; and (2) assess the severe hypotension after ACE-inhibitor application clinical impact of this relation on safety and efficacy of ACE inhibitors in the treatment of hypertensive individuals admitted to the emergency room.
178
patients through a venous cannula inserted in the
Patients and methods
forearm not used for administration of the treatment Study design to determine PRA, ACE, ANG II and aldosterone. The first 5 ml were discarded and samples for PRA This was prospectively designed study was perforand ANG II were collected into evacuated glass med in the Emergency Department of the New Gentubes with EDTA (Becton Dickinson Vacutainer Syseral Hospital in Vienna.
tems, France) and immediately stored on ice. Samples for PRA and ANG II were centrifuged at Patient selection 3000 g at 4°C for 15 min and plasma specimens of All patients admitted to the emergency department 1 ml were stored in plastic tubes at −70°C. Blood with hypertensive urgency or emergency were primsamples for ACE and serum aldosterone were colarily included to the study protocol. Hypertensive lected in silicone coated evacuated glass tubes urgency was defined as an elevation of systolic BP (Becton Dickinson) and stored at room temperature. (SBP) Ͼ210 mm Hg and/or diastolic BP (DBP) Ͼ120
All patients gave their written informed consent for mm Hg without evidence of end-organ damage.
taking the additional blood samples. Hypertensive emergency was defined as an elevation of SBP Ͼ200 mm Hg and/or DBP Ͼ110 mm Hg with Assays the evidence of end-organ damage, ie, acute congestive heart failure, stroke, aortic dissection or All radioimmunoassay incubations were set up in angina pectoris.
duplicates. Radioactivity was counted by a 1470 Exclusion criteria were intake of ACE-inhibitors Wizard gamma-counter (Wallac, Finland); the Multiwithin the last 72 hours, permanent therapy with calc software from Wallac was used for data diuretics, evidence of acute or chronic renal insufreduction. ficiency and uni-or bilateral stenosis of renal arteries. Acute renal failure was diagnosed by the PRA: Renin activity was analysed by in vitro profollowing parameters: negative previous history of duced angiotensin I (ANG I), measured with renal disease; urine osmolarity 300 ± 20 mosmol/l; radioimmunoassay kits (Sorin Biomedica, France). urinary sodium Ͼ30 mmol/l; urine/plasma osmoAll procedures were according to the protocol of the lality = 1; serum creatinine Ͼ176.8 mol/l (2 mg/dl); manufacturer, including the volumes, addition of Chronic renal failure was evident if a positive hisprotease inhibitor and set up of the ANG I radioimtory of renal disease was combined with elevated munoassay. The interassay precision was monitored serum creatinine (Ͼ176.8 mol/l [2 mg/dl]). After by calculation of coefficients of variation (CV) from the acute event duplexsonography of renal arteries control samples: kit control (CV = 10% at 1.1 angiowas performed in all patients to exclude uni-or tensin l/ml/h) and control materials obtained from bilateral stenosis of the renal arteries.
Ciba-Corning, USA. (CV = 9% both at 0.9 ng/ml/h and at 3.5 ng/ml/h). Baseline stabilization period ACE: ACE was analysed by a colorimetric method After diagnosis of hypertensive crisis all patients (ACEcolor, Fujirebio Inc, Japan) which was run on a were told to rest in a supine position and were Cobas Fara automated analyser (Hoffmann LaRoche, observed for 30 min without any antihypertensive Switzerland). Interassay CV was 2.3% at 11.6 U/l. medication. During this period, complete physical examination, electrocardiograms and laboratory ANG II: ANG II was measured by radioimmunoasevaluations to determine serum creatinine, blood say (ERIA Diagnostics Pasteur, France) after thawing urea nitrogen, creatine-kinase and electrolyte levels the samples in an ice-water bath, centrifugation in were performed. Heart rates were monitored conthe cold and extraction with phenylsilyl-silica tinuously and BP was measured every 5 min autoaccording to Nussberger et al. 15 Extraction was permatically using a non-invasive BP measurement formed on Isolute PH (EC) 100 mg/1 ml minicolums parameter unit (NIBP module; Hewlett Packard from International Sorbent Technology (UK) by Component Monitoring System, Cincinnati, OH, means of an ASPEC XL solid phase extraction USA).
machine. The extraction machine was equipped with a Peltier-cooled sample rack set at 4°C, the Treatment period eluents were cooled during the whole extraction procedure. The minicolumns were activated by subIf after this stabilization period the patients still fulsequent washing with 1 ml methanol and 1 ml disfilled inclusion criteria, the patients received 5 mg tilled water (10 ml/min). Plasma (2 m) was applied enalaprilat. Response to treatment was defined as a and columns were washed with 1 ml distilled water. reduction of SBP below 180 mm Hg and DBP below ANG II was eluted with 0.5 ml methanol (3 ml/min) 95 mm Hg within 75 min after application of enalainto glass tubes. The eluents were dried in a Turprilat. Severe hypotension was defined as reduction boVap LV Evaporator (Zymark, USA) at 37°C under of SBP or DBP Ͼ25% of the pretreatment BP.
nitrogen flow. The residues were dissolved in 0.5 ml assay buffer, centrifuged in the cold and the ANG II Blood sampling and handling radioimmunoassay was performed immediately on the supernatants according to manufacturer's Immediately before the start of antihypertensive treatment, blood samples were collected from suggestions. By addition of 125 I-angiotensin II we RAD, USA) and samples. Interassay coefficient CVs were 11% (66 pg/ml), 8% (309 pg/ml) and 5% (692 pg/ml). Table 1 illustrates the correlation between PRA, ACE, ANG II and serum ALDO in hypertensive Units: PRA, ANG II and ALDO results are reported patients. PRA correlates positively with ACE and in conventional units. SI conversions are as follows:
ANG II. A significant correlation was also observed aldosterone: ng/dl × 27.74 = pmol/l; ANG II: pg/ml between ANG II and ACE. Correlation coefficients × 1 = ng/l; PRA: ng/ml/h × 1 = g/l/h between serum ALDO and the other three factors of the RAA system did not exhibit statistical significance (Table 1 ).
Statistical analysis
All data are reported as mean s.d. unless otherwise
Overall relation between BP reduction and the indicated. Comparisons of variables between groups activity of the RAA system were performed using unpaired Student's t-test for Table 2 illustrates the relation between the extent of continuous data and 2 test for categorical data. The SBP or DBP reduction and the pretreatment levels least square method was used to exploratively examof PRA, ACE, ANG II and ALDO. The extent of SBP ine for correlation between laboratory values and for as well as DBP reduction was correlated with prerelation between the extent of BP reduction and pretreatment levels of PRA and ANG II. No significant treatment levels of PRA, ACE, ANG II and ALDO.
correlations were observed between pretreatment Receiver-operator analysis (ROC) was used for the levels of ACE or ALDO and extent of BP reduction. determination of the optimal cut-off value of PRA with regard to treatment response after enalaprilat.
16,17 All analyses were calculated on SPSS 6.0 Response to treatment (Figure 1 ) (SPSS Inc, Cincinnati, OH, USA). A probability level
In 20 (57%) out of 35 patients the treatment goal of 5% was considered statistically significant.
listed above was reached. Fifteen (43%) patients did not achieve goal of treatment 75 min after appli-
Results
cation of 5 mg enalaprilat. The average magnitude of SBP decrease in responders within 75 min was Patients characteristics 46.1 ± 3.6 mm Hg, whereas in non-responders SBP Thirty-five patients (23 males, 12 females) with decrease was 17.3 ± 3.4 mm Hg. Average DBP hypertensive urgencies (n = 15; 43%) or emergencies reduction in responders and non-responders was (n = 20; 57%) were enrolled into the study. The 31.8 ± 1.7 mm Hg and 10.6 ± 3.0 mm Hg, respectmean age was 55 years (range: 34 to 82 years).
ively. Mean arterial pressure decreased in Reasons for seeking medical aid included cardioresponders by 36.5 ± 1.8 mm Hg and in nonvascular emergencies (angina pectoris: n = 6; 17%, responders by 12.7 ± 2.5 mm Hg, respectively. congestive heart failure: n = 5; 14%), neurological
The observed magnitudes of SBP and DBP emergencies (n = 9; 25%) or hypertensive urgencies decrease were significantly different between (epistaxis: n = 2; 6%; feeling of general illness: n = 7, 20%, palpitations n = 3; 9%, nausea: n = 3; 9%). trations was 17.3 ± 7.8 ng/dl (range: 2.5-33.1 ng/dl). 1.1 ± 2.2 ng/ml h. The observed difference of renin activity between responders and non-responders was statistically significant at a P-value of Ͻ0.001 (Figure 2) . A cut-off value of 2.2 ng/ml/h was found to discriminate best between responders and nonresponders ( Figure 3 ). This value represented a sensitivity and specificity of 0.86, respectively (Table 4) .
ACE:
In responders ACE ranged fom 7.0 to 19.1 U/l, the mean was 12.8 ± 3.5 U/l. In nonresponders ACE ranged from 2.5 to 15.0 U/l, the mean was 8.2 ± 4.8 U/l. The observed difference of serum ACE concentration between responders and non-responders was statistically significant at at Pvalue of 0.003.
ANG II:
In responders ANG II ranged from 1.0 to 22.9 pg/ml, the mean was 8.7 ± 6.2 pg/ml. In nonresponders serum ANG II ranged from undetectable (Ͻ0.95) to 13.3 pg/ml, the mean was 5.0 ± 3.8 pg/ml. Differences of ANG II concentrations between responders and non-responders were at the limit of the chosen significance (P = 0.04).
Serum ALDO:
In responders serum ALDO ranged from 2.5 to 28 ng/dl, the mean was 15.5 ± 7.34 ng/dl. responders and non-responders (P Ͻ 0.001 for SBP and P Ͻ 0.001 for DBP, respectively.
Characteristics of non-responders and responders
General characteristics: Table 3 illustrates general clinical characteristics of non-responders and responders. The groups were well balanced with regard to age, gender, BP on admission, presenting clinical symptom, serum electrolytes and serum creatinine.
Plasma renin activity:
In responders, renin activity ranged from 0.0 to 8.4 ng/ml/h, the mean was
Discussion
Our study demonstrates that the extent of BP reduction after enalaprilat application is positively correlated to pretreatment levels of plasma renin and ANG II in patients with hypertensive crises. Hodsman et al 8 reported similar correlation coefficients between PRA or ANG II and percentage change in mean arterial BP after first dose of captopril. An even higher correlation coefficient (r = 0.83) was noted by Brown et al, 18 who demonstrated a significant relation between saralasin-induced BP reduction and pretreatment ANG II concentrations. According to our own and previously published data the most pronounced fall in BP is observed in patients with the highest activity of the RAA system. 19 Removal of the vasoconstrictor effect of ANG II is one of the major factors in the reduction of BP in the first hours after ACE inhibition. In contrast, low PRA and ANG II concentrations are associated The relation between RAA system and fall of BP after enalaprilat is more controversially discussed in patients with essential hypertension.
13,14 Moreover, as intravenous enalaprilat has been recommended was evident in these patients. [20] [21] [22] [23] We therefore assume that the circulatory RAA system did not contribute to the hypertensive status in about 40% of all patients with hypertensive crises.
These findings have important clinical impliIn non-responders serum ALDO ranged from 7.7 to cations for the treatment of patients with hyperten-33.1 ng/dl, the mean was 19.68 ± 8.03 ng/dl. Differsive urgencies and emergencies. As primary nonences of serum ALDO concentrations between response to enalaprilat indicates a low activity of the responders and non-responders did not exhibit stat-RAA system, repetitive application of enalaprilat or istical significance (P = 0.12).
increase of dosage is ineffective and may result in an unnecessary delay of an effective therapy. Our results are in line with previously published data Characteristics of patients with severe demonstrating that increase of dosage did not alter hypotension the percentage of responders to enalaprilat. 24 In patients with hypertensive crises a 20-25% Nine patients exhibited a BP lowering Ͼ25% of the pretreatment levels. In patients with severe hypotenreduction in arterial BP over 60-90 min is a reasonable therapeutic goal. 25, 26 A more rapid and prosion the percentage of cardiovascular events was significantly higher compared to patients with normal nounced lowering of BP may increase the risk for further organ damage. BP response (7 vs 2; P = 0.007). In contrast, the number of urgencies was significantly higher in patients Analysing the group of responders according to this therapeutic guideline we observed a more than with normal BP response compared to those with severe hypotension (8 vs 1; P = 0.006). In these 25% reduction of arterial BP in 13 (37%) patients. Pretreatment concentration of ANG II was signifipatients ANG II concentration was significantly higher compared to patients with a less pronounced cantly higher in these patients. We therefore assume that in the group of responders the risk for an excessreduction (Ͻ25%) of mean arterial BP (Table 5 ). All other factors of the RAA system did not exhibit sigive BP reduction increases with higher activity of the RAA system. As 37% of all patients exhibit a nificant differences. 
